D.E. Shaw & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

D.E. Shaw & Co’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-54,625	Closed	-$204K	–	5063
2024 Q3	$204K	Sell	54,625 -116,383	-68%	-$555K	﹤0.01%	4149
2024 Q2	$958K	Sell	171,008 -48,803	-22%	-$213K	﹤0.01%	3232
2024 Q1	$1.15M	Buy	219,811 +56,321	+34%	+$309K	﹤0.01%	3004
2023 Q4	$855K	Buy	163,490 +53,490	+49%	+$528K	﹤0.01%	3239
2023 Q3	$1.73M	Sell	110,000 -17,579	-14%	-$316K	﹤0.01%	2687
2023 Q2	$2.48M	Buy	127,579 +39,635	+45%	+$940K	﹤0.01%	2457
2023 Q1	$2.49M	Buy	87,944 +33,027	+60%	+$980K	﹤0.01%	2519
2022 Q4	$1.61M	Buy	54,917 +1,023	+2%	+$32.5K	﹤0.01%	3110
2022 Q3	$1.42M	Sell	53,894 -43,970	-45%	-$1.61M	﹤0.01%	3306
2022 Q2	$4.35M	Sell	97,864 -17,813	-15%	-$818K	0.01%	2300
2022 Q1	$5.72M	Buy	115,677 +24,978	+28%	+$1.2M	0.01%	2158
2021 Q4	$4.62M	Sell	90,699 -1,404	-2%	-$72.7K	﹤0.01%	2459
2021 Q3	$5.14M	Sell	92,103 -32,865	-26%	-$1.62M	﹤0.01%	2079
2021 Q2	$5.35M	Buy	124,968 +16,807	+16%	+$694K	﹤0.01%	1971
2021 Q1	$4.51M	Buy	108,161 +49,174	+83%	+$2.28M	﹤0.01%	1923
2020 Q4	$2.75M	Buy	58,987 +28,861	+96%	+$1.35M	﹤0.01%	2340
2020 Q3	$1.28M	Sell	30,126 -40,113	-57%	-$1.75M	﹤0.01%	2697
2020 Q2	$3.37M	Sell	70,239 -5,205	-7%	-$260K	﹤0.01%	1984
2020 Q1	$3.47M	Buy	75,444 +4,052	+6%	+$203K	0.01%	1739
2019 Q4	$4.29M	Sell	71,392 -16,384	-19%	-$977K	﹤0.01%	1849
2019 Q3	$4.96M	Sell	87,776 -29,984	-25%	-$1.69M	0.01%	1650
2019 Q2	$6.56M	Sell	117,760 -84,147	-42%	-$4.39M	0.01%	1409
2019 Q1	$10.2M	Sell	201,907 -83,411	-29%	-$3.71M	0.01%	1091
2018 Q4	$11.5M	Buy	285,318 +156,499	+121%	+$8.07M	0.02%	1002
2018 Q3	$8.93M	Buy	128,819 +48,344	+60%	+$3.67M	0.01%	1187
2018 Q2	$6.09M	Buy	80,475 +2,513	+3%	+$158K	0.01%	1395
2018 Q1	$4.11M	Buy	77,962 +36,534	+88%	+$2.12M	0.01%	1540
2017 Q4	$2.21M	Buy	+41,428	New	+$2.31M	﹤0.01%	2073
2017 Q2	–	Sell	-7,843	Closed	-$650K	–	3582
2017 Q1	$650K	Buy	+7,843	New	+$583K	﹤0.01%	2589
2016 Q3	–	Sell	-5,500	Closed	-$213K	–	3595
2016 Q2	$213K	Buy	+5,500	New	+$229K	﹤0.01%	3169
2015 Q3	–	Sell	-7,465	Closed	-$621K	–	3944
2015 Q2	$604K	Sell	7,465 -22,755	-75%	-$1.48M	﹤0.01%	3057
2015 Q1	$1.27M	Buy	30,220 +2,842	+10%	+$80.6K	﹤0.01%	2373
2014 Q4	$424K	Sell	27,378 -7,996	-23%	-$102K	﹤0.01%	3435
2014 Q3	$447K	Buy	+35,374	New	+$439K	﹤0.01%	3435

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

D.E. Shaw & Co's EGRX Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 54,625 shares — an estimated $204K sold.

D.E. Shaw & Co first reported a position in EGRX in Q3 2014 and held it in 34 quarters. The position peaked at $11.5M in Q4 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

D.E. Shaw & Co reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
D.E. Shaw & Co sold 54,625 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $204K.
D.E. Shaw & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 34 quarters.
D.E. Shaw & Co's Eagle Pharmaceuticals, Inc. position peaked at $11.5M in Q4 2018.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.